[3][better source needed] In January 2012, the company was named "the top biotechnology takeover target in 2012" through an industry survey.
[2] Sorafenib, co-developed and co-marketed with Bayer and sold under the trade name Nexavar, is a drug approved in the United States for the treatment of advanced renal cell carcinoma (kidney cancer) in 2005, and for the treatment of inoperable hepatocellular carcinoma, the most common form of liver cancer, in 2007.
[7][8] Sorafenib has also been evaluated in other types of cancer, including those of the thyroid (as a treatment of last resort) and breast (in comparison to capecitabine).
The most commonly reported adverse reactions (incidence ≥ 30%) are fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and pyrexia.
[12] Regorafenib (marketed under the trade name Stivarga), is currently being studied as a potential treatment option in multiple tumor types.
The drug combination failed to increase progression free survival of patients with advanced breast cancer.